SCHEMBL16573285

SCHEMBL16573285

CC(=S)Nc1ccc(CCC(N)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
LMNA P02545 1/20 0.48
AOC3 Q16853 1/20 0.47
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
TAS2R38 P59533 1/20 0.44
POLB P06746 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
FFAR1 O14842 1/20 0.42
MAPT P10636 3/20 0.42
RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16573271 0.92 POLB (0.49) ALDH1A1AOC3HDAC3HDAC4HDAC1
SCHEMBL7688792 0.90 ALDH1A1 (0.47) ALDH1A1LMNAAOC3HDAC3HDAC4
SCHEMBL30779193 0.86 AOC3 (0.60) ALDH1A1LMNAAOC3HDAC3HDAC4
SCHEMBL20459167 0.82 PEPD (0.53) ALDH1A1LMNAAOC3HDAC3HDAC4
SCHEMBL16573306 0.82 HDAC1 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10760567 0.79 ALDH1A1 (0.53) ALDH1A1LMNAAOC3HDAC3HDAC4
SCHEMBL987285 0.79 HDAC3 (0.72) ALDH1A1LMNAHDAC3HDAC4HDAC1
SCHEMBL7328828 0.78 POLB (0.53) ALDH1A1TAS2R38POLBFFAR1NR1H4
SCHEMBL4512426 0.78 EPHX2 (0.52) ALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL16573272 0.76 EPHX2 (0.55) ALDH1A1POLBMAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2444085-B1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer UNIV CALIFORNIA (US) 2015-03-18 EP disclosed